GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Neurocrine Biosciences Inc (BSP:N1BI34) » Definitions » Cyclically Adjusted PB Ratio

Neurocrine Biosciences (BSP:N1BI34) Cyclically Adjusted PB Ratio : 14.54 (As of May. 03, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Neurocrine Biosciences Cyclically Adjusted PB Ratio?

As of today (2024-05-03), Neurocrine Biosciences's current share price is R$36.64. Neurocrine Biosciences's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was R$2.52. Neurocrine Biosciences's Cyclically Adjusted PB Ratio for today is 14.54.

The historical rank and industry rank for Neurocrine Biosciences's Cyclically Adjusted PB Ratio or its related term are showing as below:

BSP:N1BI34' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 1.62   Med: 15.53   Max: 47.47
Current: 13.84

During the past years, Neurocrine Biosciences's highest Cyclically Adjusted PB Ratio was 47.47. The lowest was 1.62. And the median was 15.53.

BSP:N1BI34's Cyclically Adjusted PB Ratio is ranked worse than
97.11% of 657 companies
in the Drug Manufacturers industry
Industry Median: 1.81 vs BSP:N1BI34: 13.84

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Neurocrine Biosciences's adjusted book value per share data for the three months ended in Mar. 2024 was R$5.907. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is R$2.52 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Neurocrine Biosciences Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Neurocrine Biosciences's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurocrine Biosciences Cyclically Adjusted PB Ratio Chart

Neurocrine Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 31.88 22.21 14.36 15.67 13.72

Neurocrine Biosciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.48 10.95 12.32 13.72 13.66

Competitive Comparison of Neurocrine Biosciences's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Neurocrine Biosciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neurocrine Biosciences's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Neurocrine Biosciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Neurocrine Biosciences's Cyclically Adjusted PB Ratio falls into.



Neurocrine Biosciences Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Neurocrine Biosciences's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=36.64/2.52
=14.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurocrine Biosciences's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Neurocrine Biosciences's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=5.907/129.4194*129.4194
=5.907

Current CPI (Mar. 2024) = 129.4194.

Neurocrine Biosciences Quarterly Data

Book Value per Share CPI Adj_Book
201406 0.349 100.560 0.449
201409 0.345 100.428 0.445
201412 0.361 99.070 0.472
201503 0.892 99.621 1.159
201506 0.847 100.684 1.089
201509 1.016 100.392 1.310
201512 0.955 99.792 1.239
201603 0.882 100.470 1.136
201606 0.752 101.688 0.957
201609 0.658 101.861 0.836
201612 0.608 101.863 0.772
201703 0.442 102.862 0.556
201706 0.645 103.349 0.808
201709 0.615 104.136 0.764
201712 0.690 104.011 0.859
201803 0.665 105.290 0.817
201806 0.787 106.317 0.958
201809 1.014 106.507 1.232
201812 1.028 105.998 1.255
201903 0.861 107.251 1.039
201906 1.019 108.070 1.220
201909 1.285 108.329 1.535
201912 1.417 108.420 1.691
202003 1.844 108.902 2.191
202006 2.314 108.767 2.753
202009 2.325 109.815 2.740
202012 3.098 109.897 3.648
202103 3.595 111.754 4.163
202106 3.400 114.631 3.839
202109 3.748 115.734 4.191
202112 4.094 117.630 4.504
202203 3.624 121.301 3.867
202206 3.758 125.017 3.890
202209 4.214 125.227 4.355
202212 4.641 125.222 4.797
202303 4.499 127.348 4.572
202306 4.608 128.729 4.633
202309 5.035 129.860 5.018
202312 5.540 129.419 5.540
202403 5.907 129.419 5.907

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Neurocrine Biosciences  (BSP:N1BI34) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Neurocrine Biosciences Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Neurocrine Biosciences's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Neurocrine Biosciences (BSP:N1BI34) Business Description

Traded in Other Exchanges
Address
12780 El Camino Real, San Diego, CA, USA, 92130
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.

Neurocrine Biosciences (BSP:N1BI34) Headlines

No Headlines